Template:BerkiGEM2007 WikiPlaying
From 2007.igem.org
(Difference between revisions)
Line 130: | Line 130: | ||
position:absolute; | position:absolute; | ||
left:270px; | left:270px; | ||
- | top: | + | top:561px; |
width:502px; | width:502px; | ||
height:450px; | height:450px; | ||
Line 146: | Line 146: | ||
position:absolute; | position:absolute; | ||
left:226px; | left:226px; | ||
- | top: | + | top:459px; |
width:420px; | width:420px; | ||
height:125px; | height:125px; | ||
Line 187: | Line 187: | ||
position:absolute; | position:absolute; | ||
left:206px; | left:206px; | ||
- | top: | + | top:606px; |
width:164px; | width:164px; | ||
height:134px; | height:134px; | ||
Line 203: | Line 203: | ||
position:absolute; | position:absolute; | ||
left:773px; | left:773px; | ||
- | top: | + | top:440px; |
width:107px; | width:107px; | ||
height:120px; | height:120px; | ||
Line 211: | Line 211: | ||
position:absolute; | position:absolute; | ||
left:832px; | left:832px; | ||
- | top: | + | top:823px; |
width:103px; | width:103px; | ||
height:108px; | height:108px; | ||
Line 227: | Line 227: | ||
position:absolute; | position:absolute; | ||
left:777px; | left:777px; | ||
- | top: | + | top:978px; |
width:107px; | width:107px; | ||
height:149px; | height:149px; | ||
Line 252: | Line 252: | ||
position:absolute; | position:absolute; | ||
left:228px; | left:228px; | ||
- | top: | + | top:1161px; |
width:214px; | width:214px; | ||
height:125px; | height:125px; | ||
Line 260: | Line 260: | ||
position:absolute; | position:absolute; | ||
left:616px; | left:616px; | ||
- | top: | + | top:1160px; |
width:141px; | width:141px; | ||
height:112px; | height:112px; | ||
Line 332: | Line 332: | ||
position:absolute; | position:absolute; | ||
left:15px; | left:15px; | ||
- | top: | + | top:464px; |
width:149px; | width:149px; | ||
height:32px; | height:32px; | ||
Line 340: | Line 340: | ||
position:absolute; | position:absolute; | ||
left:15px; | left:15px; | ||
- | top: | + | top:615px; |
width:138px; | width:138px; | ||
height:22px; | height:22px; | ||
Line 348: | Line 348: | ||
position:absolute; | position:absolute; | ||
left:16px; | left:16px; | ||
- | top: | + | top:766px; |
width:136px; | width:136px; | ||
height:24px; | height:24px; | ||
Line 356: | Line 356: | ||
position:absolute; | position:absolute; | ||
left:17px; | left:17px; | ||
- | top: | + | top:918px; |
width:139px; | width:139px; | ||
height:22px; | height:22px; | ||
Line 364: | Line 364: | ||
position:absolute; | position:absolute; | ||
left:16px; | left:16px; | ||
- | top: | + | top:1071px; |
width:138px; | width:138px; | ||
height:24px; | height:24px; | ||
Line 372: | Line 372: | ||
position:absolute; | position:absolute; | ||
left:16px; | left:16px; | ||
- | top: | + | top:1223px; |
width:142px; | width:142px; | ||
height:27px; | height:27px; | ||
Line 392: | Line 392: | ||
position:absolute; | position:absolute; | ||
left:764px; | left:764px; | ||
- | top: | + | top:1289px; |
width:183px; | width:183px; | ||
height:52px; | height:52px; | ||
Line 419: | Line 419: | ||
top:201px; | top:201px; | ||
width:956px; | width:956px; | ||
- | height: | + | height:81px; |
z-index:33; | z-index:33; | ||
} | } | ||
Line 425: | Line 425: | ||
position:absolute; | position:absolute; | ||
left:16px; | left:16px; | ||
- | top: | + | top:1332px; |
- | width: | + | width:541px; |
height:26px; | height:26px; | ||
z-index:34; | z-index:34; | ||
+ | } | ||
+ | #apDiv41 { | ||
+ | position:absolute; | ||
+ | left:5px; | ||
+ | top:281px; | ||
+ | width:950px; | ||
+ | height:160px; | ||
+ | z-index:35; | ||
} | } | ||
--> | --> | ||
Line 475: | Line 483: | ||
<div id="apDiv39"></div> | <div id="apDiv39"></div> | ||
<div id="apDiv40">Best viewed in the most recent version of firefox, because IE sucks. </div> | <div id="apDiv40">Best viewed in the most recent version of firefox, because IE sucks. </div> | ||
+ | <div id="apDiv41"><strong>The global demand and importance</strong> for cheap, available, and disease free blood substitutes is undisputed. There are currently no red blood cell substitutes approved for clinical use in the US or the UK, and whole blood is almost always in short supply. Underdeveloped countries that need blood the most simply don’t have the infrastructure to support donation and storage, in addition a sizeable fraction of the population are disease carriers. We are developing an innovative and cheap blood substitute based on engineered <em>E. coli</em> with all the critical properties of human erythrocytes. These include the ability to safely exist in the bloodstream, carry oxygen, and be stored for prolonged periods in a freeze-dried state.</div> | ||
</body> | </body> | ||
</html> | </html> |
Revision as of 08:03, 7 October 2007
Oxygen Transport
Immunity
Storage
System Controller
Kill Switch
Antioxidants
Growth Control
Begin Project Tour
Best viewed in the most recent version of firefox, because IE sucks.
The global demand and importance for cheap, available, and disease free blood substitutes is undisputed. There are currently no red blood cell substitutes approved for clinical use in the US or the UK, and whole blood is almost always in short supply. Underdeveloped countries that need blood the most simply don’t have the infrastructure to support donation and storage, in addition a sizeable fraction of the population are disease carriers. We are developing an innovative and cheap blood substitute based on engineered E. coli with all the critical properties of human erythrocytes. These include the ability to safely exist in the bloodstream, carry oxygen, and be stored for prolonged periods in a freeze-dried state.